Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GABRG1 drug discovery. As a complex multimeric ion channel subunit, GABRG1 requires precise conformational presentation — cell-based assays are the only way to preserve native structure. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GABRG1 Recombinant Protein (Extracellular Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. Also available as Membrane Prep for conformational studies. |
View GABRG1 Products |
| Gene Delivery | GABRG1 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction. Native glycosylation. Cell-based assays preserve receptor conformation. |
View GABRG1 Products |
| Benchmark Ab | Anti-GABRG1 (Research Grade Recombinant / Control Antibody) Sequence-defined positive control for assay validation. |
View GABRG1 Products |
| Validator | GABRG1 siRNA Set (3 unique sequences) For subunit-specific knockdown verification and specificity screening. |
View GABRG1 Products |
| Complex Partner | GABRA2 (Alpha-2 Subunit) Co-assembles with GABRG1; defines extrasynaptic receptor pharmacology. |
View GABRA2 Products |
| Complex Partner | GABRB2 (Beta-2 Subunit) Essential structural subunit for functional pentameric GABA-A assembly. |
View GABRB2 Products |
| Complex Partner | GABRA1 (Alpha-1 Subunit) Core structural alpha subunit often co-expressed with gamma subunits in functional pentamers. |
View GABRA1 Products |
| Paralog Control | GABRG2 (Gamma-2 Subunit) Predominant synaptic isoform; critical for selectivity counter-screening. |
View GABRG2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pentameric Complex Assembly & Conformational Integrity (requires multi-subunit co-expression) | Lentivirus co-transduction system compatible with GABRA/GABRB partners; maintains native stoichiometry and ensures correct multimeric assembly. |
| Subunit Selectivity & Counter Screening (GABRG1 vs GABRG2/G3 discrimination) | Unique GABRG1 extracellular loop antigens, Sequence Verified by Mass Spectrometry. GABRG2/G3 ortholog panels available for selectivity validation. |
| Functional Cell-based Validation (Chloride flux / Electrophysiology) | Stable cell lines expressing defined alpha-beta-gamma1 stoichiometry; Endotoxin controlled. |
| Specificity Controls & False Positive Elimination (off-target subunit screening) | Validated siRNA targeting non-conserved GABRG1 regions; theoretical MW confirmed. Clinical Benchmark Antibodies included for assay normalization. |
Live GABRG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GABA-A receptor subunit-selective therapeutics is intensifying, with major players shifting focus from traditional non-selective benzodiazepines to precision modulators targeting extrasynaptic populations. As first-generation alpha-selective modulators reach late-stage trials, the next wave of R&D is targeting gamma-subunit composition to distinguish between synaptic phasic and extrasynaptic tonic inhibition. GABRG1-containing receptors represent a distinct pharmacological population with unique neurosteroid sensitivity, driving renewed interest in epilepsy and neurodegenerative indications. Additionally, the pursuit of precise anxiolytic effects without the sedative and addictive liabilities associated with broad-spectrum GABAergic modulation is accelerating the development of subtype-selective small molecules and gene therapies. Ongoing research into functional mutations, such as the rs17852913 variant documented in UniProt, continues to illuminate the genetic basis of GABRG1-related neurological disorders.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Subunit-Selective Small Molecule (PAM/NAM) | Sage Therapeutics, Marinus Pharma, Bionomics, Sanofi, Cerevel Therapeutics, Academic Consortia | Epilepsy, Status Epilepticus, Fragile X, Anxiety, Alcohol Dependence | Pentameric Assembly Assay (Need Lentivirus stable lines with defined subunit ratios for selectivity screening) |
| Neurosteroid Modulators | Sage Therapeutics | Post-Partum Depression, Refractory Seizures | Extrasynaptic Receptor Expression (Need GABRG1-specific cell lines vs GABRG2 controls) |
| Gene/Cell Therapy (AAV/Lentivirus) | Encoded Therapeutics, Novartis, Early-stage Biotech | Refractory Epilepsy, Genetic Epilepsies | Expression Validation (Need specific Benchmark Abs & siRNA for trafficking studies) |
| Monoclonal Antibody | Academic & Biotech | Target Validation / Research | Binding Assays (Need High-Purity HEK293 Expressed Proteins) |